News
Looking back on software development stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including ...
Aldeyra's Reproxalap progresses towards FDA approval, with a potential $100M AbbVie deal. There’s still upside potential, ...
IDEX Corporation delivers steady cash flow and high margins from niche industrial markets, supported by a diversified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback